Netherlands· NL-e83d93b49946
Xultophy 100 eenheden/ml + 3,6 mg/ml oplossing voor injectie
A insulin degludec and liraglutide product containing insuline degludec + liraglutide, registered in Netherlands by Novo Nordisk A.S.. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Insulin degludec and liraglutide is registered in 12 of 19 countries.
Countries holding a registration under ATC A10AE56 (insulin degludec and liraglutide), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Insulin degludec and liraglutide · ATC A10AE56
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- INSULINE DEGLUDEC + LIRAGLUTIDE
- Manufacturer
- Novo Nordisk A.S.
- Country
- Netherlands (NL)
- ATC code
- A10AE56
- ATC class
- Insulin degludec and liraglutide
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/14/947
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin degludec and liraglutide in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXULTOPHYNovo Nordisk A/S, Bagsvaerd
- NorwayXultophyOrifarm AS
- SpainXULTOPHY 100 U/ML + 3,6 MG/ML SOLUCION INYECTABLENovo Nordisk A/S
- FinlandXultophyNovo Nordisk A/S
- FranceXULTOPHY 100 unités/ml + 3,6 mg/ml, solution injectableNOVO NORDISK (DANEMARK)
- United KingdomXultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pensNovo Nordisk Ltd
- IrelandXultophy 100 units/mL + 3.6 mg/mL solution for injection.Novo Nordisk A/S
- IcelandXultophyNovo Nordisk A/S*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Xultophy
- Norway · Xultophy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/325c108f-e5f4-4475-a50c-5b12f948ddaa GET /v1/drugs/325c108f-e5f4-4475-a50c-5b12f948ddaa?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/xultophy-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Insulin degludec and liraglutide",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp113858",
"excipients": [
"FENOL",
"GLYCEROL (E 422)",
"NATRIUMHYDROXIDE (E 524)",
"WATER VOOR INJECTIE",
"ZINKDIACETAAT 2-WATER (E 650)",
"ZOUTZUUR (E 507)"
],
"substances": [
"INSULINE DEGLUDEC",
"LIRAGLUTIDE"
],
"leaflet_url": null,
"authorised_at": "2014/09/18",
"procedure_number": "EMEA/H/C/002647",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/14/947",
"additional_monitoring": "N"
}See everything about insulin degludec and liraglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.